Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study

Affiliations

¹ Center for Vascular Anomalies, Institut Roi Albert II, Department of Medical Oncology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
² Center for Vascular Anomalies, Division of Plastic Surgery, Cliniques universitaires Saint Luc, University of Louvain, 10 avenue Hippocrate, B-1200, Brussels, Belgium.
³ Department of Pediatric Hemato-oncology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
⁴ Center for Vascular Anomalies, Department of Pediatric Hemato-oncology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
⁵ Center for Vascular Anomalies, Department of Head and Neck Surgery, Cliniques universitaires Saint-Luc, University of Louvain, Brussels, Belgium.
⁶ Department of Pediatric Hemato-oncology, CHR Citadelle, Liège, Belgium.
⁷ Department of Pediatric Cardiology, CHRU Lille, Lille, France.
⁸ Division of Pediatric Radiology, Cliniques universitaires Saint-Luc, University of Louvain, Brussels, Belgium.
⁹ Division of Interventional Radiology, Cliniques universitaires Saint-Luc, University of Louvain, Brussels, Belgium.
¹⁰ Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium.
¹¹ Center for Vascular Anomalies, Division of Plastic Surgery, Cliniques universitaires Saint Luc, University of Louvain, 10 avenue Hippocrate, B-1200, Brussels, Belgium. laurence.boon@uclouvain.be.
¹² Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium. laurence.boon@uclouvain.be.

PMID: 30373605
PMCID: PMC6206885
DOI: 10.1186/s13023-018-0934-z

Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study

Jennifer Hammer et al. Orphanet J Rare Dis. 2018.

. 2018 Oct 29;13(1):191.

doi: 10.1186/s13023-018-0934-z.

Authors

Affiliations

¹ Center for Vascular Anomalies, Institut Roi Albert II, Department of Medical Oncology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
² Center for Vascular Anomalies, Division of Plastic Surgery, Cliniques universitaires Saint Luc, University of Louvain, 10 avenue Hippocrate, B-1200, Brussels, Belgium.
³ Department of Pediatric Hemato-oncology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
⁴ Center for Vascular Anomalies, Department of Pediatric Hemato-oncology, Cliniques universitaires Saint Luc, University of Louvain, Brussels, Belgium.
⁵ Center for Vascular Anomalies, Department of Head and Neck Surgery, Cliniques universitaires Saint-Luc, University of Louvain, Brussels, Belgium.
⁶ Department of Pediatric Hemato-oncology, CHR Citadelle, Liège, Belgium.
⁷ Department of Pediatric Cardiology, CHRU Lille, Lille, France.
⁸ Division of Pediatric Radiology, Cliniques universitaires Saint-Luc, University of Louvain, Brussels, Belgium.
⁹ Division of Interventional Radiology, Cliniques universitaires Saint-Luc, University of Louvain, Brussels, Belgium.
¹⁰ Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium.
¹¹ Center for Vascular Anomalies, Division of Plastic Surgery, Cliniques universitaires Saint Luc, University of Louvain, 10 avenue Hippocrate, B-1200, Brussels, Belgium. laurence.boon@uclouvain.be.
¹² Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium. laurence.boon@uclouvain.be.

PMID: 30373605
PMCID: PMC6206885
DOI: 10.1186/s13023-018-0934-z

Abstract

Background: Extensive and complex vascular malformations often cause chronic pain and severe functional restraint. Conventional treatments, such as surgery and/or sclerotherapy, are rarely curative, underscoring the great need for new therapeutic modalities. Recent preclinical and clinical data demonstrated that sirolimus could offset the progression of vascular malformations and significantly improve quality of life of patients through inhibition of the Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathway. The purpose of this prospective study was to assess the efficacy and safety of this treatment in patients with extensive or complex slow-flow vascular malformations.

Methods: Sirolimus was administered orally on a continuous dosing schedule with pharmacokinetic-guided target serum concentration level of 10 to 15 ng/ml. Patients were seen every month for the first three months and subsequently every three months. The primary endpoints were safety and efficacy, based on clinical, biological and radiological evaluations, as well as a quality of life questionnaire.

Results: Nineteen patients, from 3 to 64 years old, with lymphatic (LM), venous (VM) or complex slow-flow malformations, refractory to standard care, were enrolled and received sirolimus continuously. After 12 months of follow-up, 16 patients were available for assessment of efficacy and safety: all had a significant and rapid improvement of their symptoms and quality of life. In two patients, sirolimus treatment permitted sclerotherapy and surgery, initially evaluated unfeasible. Sirolimus was well tolerated, with mucositis as the most common (10% of patients) grade 3 adverse event.

Conclusions: Sirolimus was efficient in extensive LM, VM and/or complex malformations that were refractory to conventional treatments and was well tolerated.

Keywords: Complex vascular malformation; Extensive vascular anomaly; Lymphatic malformation; Rapamycin; Sirolimus; Slow-flow anomaly; Venous malformation.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study (NCT01811667; EudraCT 2012–001262-15) was approved by the Ethics Committee of the Cliniques universitaires Saint-Luc, Brussels, Belgium. Each patient or patient’s parent signed an informed consent after receiving a summary explaining the procedure of the study. The trial was also registered at clinicaltrials.gov under the name VASCA-LM.

Consent for publication

Each patient or patient’s parent signed a consent for publication.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

**Fig. 1**
Patient #3 with a cervico-facial microcystic LM before initiation of sirolimus (a) and after 12 months of treatment (b)

**Fig. 2**
Patient #17 with a capillaro-lymphatico-venous malformation with hypertrophy (Klippel-Trenaunay syndrome) before initiation of sirolimus (a) and after 6 months of treatment (b)

**Fig. 3**
Visual Analogue Scale (continuous pain) results for all patients

**Fig. 5**
Classical MRI sequences and 3D-volumes of the malformation (patient #15) before initiation of sirolimus (a, c) and after 12 months of treatment (**b, d**). Notice volume reduction from 14 cm³ to 12,3 cm³

See this image and copyright information in PMC

Cited by

Cellular and molecular mechanisms of PIK3CA-related vascular anomalies.
Le Cras TD, Boscolo E. Le Cras TD, et al. Vasc Biol. 2019 May 28;1(1):H33-H40. doi: 10.1530/VB-19-0016. eCollection 2019. Vasc Biol. 2019. PMID: 32923951 Free PMC article. Review.
Bockenheimer disease is associated with a TEK variant.
Sudduth CL, Konczyk DJ, Smits PJ, Eng W, Al-Ibraheemi A, Upton J, Greene AK. Sudduth CL, et al. Cold Spring Harb Mol Case Stud. 2021 Dec 9;7(6):a006119. doi: 10.1101/mcs.a006119. Print 2021 Dec. Cold Spring Harb Mol Case Stud. 2021. PMID: 34649969 Free PMC article.
Magnitude and relevance of change in health-related quality of life in patients with vascular malformations treated with sirolimus.
Harbers VEM, Bouwman FCM, van Rijnsoever IMP, Verhoeven BH, van der Vleuten CJM, Schultze Kool LJ, de Laat PCJ, van der Horst CMAM, Kievit W, Te Loo DMWM. Harbers VEM, et al. Front Med (Lausanne). 2023 Apr 20;10:1155476. doi: 10.3389/fmed.2023.1155476. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37153086 Free PMC article.
MEK inhibition reduced vascular tumor growth and coagulopathy in a mouse model with hyperactive GNAQ.
Schrenk S, Bischoff LJ, Goines J, Cai Y, Vemaraju S, Odaka Y, Good SR, Palumbo JS, Szabo S, Reynaud D, Van Raamsdonk CD, Lang RA, Boscolo E. Schrenk S, et al. Nat Commun. 2023 Apr 6;14(1):1929. doi: 10.1038/s41467-023-37516-7. Nat Commun. 2023. PMID: 37024491 Free PMC article.
Effectiveness and safety of sirolimus in the treatment of venous malformations: A meta-analysis of prospective studies.
Wang G, Lu W, Zhu Y, Wang C, Yang X. Wang G, et al. J Vasc Surg Venous Lymphat Disord. 2025 Jul 5;13(6):102284. doi: 10.1016/j.jvsv.2025.102284. Online ahead of print. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 40619100 Free PMC article. Review.

See all "Cited by" articles

References

1. Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. ISSVA board and scientific committee. Vascular anomalies classification: recommendations from the International Society for the Study of vascular anomalies. Pediatrics. 2015;136:203–214. doi: 10.1542/peds.2014-3673. - DOI - PubMed
1. Boon LM, Ballieux F, Vikkula M. Pathogenesis of vascular anomalies. Clin Plast Surg. 2011;38:7–19. doi: 10.1016/j.cps.2010.08.012. - DOI - PMC - PubMed
1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412–422. doi: 10.1097/00006534-198203000-00002. - DOI - PubMed
1. Greene AK, Liu AS, Mulliken JB, Chalace K, Fishman SJ. Vascular anomalies in 5621 patients: guidelines for referral. J Pediatr Surg. 2011;46:1784–1789. doi: 10.1016/j.jpedsurg.2011.05.006. - DOI - PubMed
1. Vikkula M, Boon LM, Carraway KL, Calvert JT, Diamonti AJ, Goumnerov B, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87:1181–1190. doi: 10.1016/S0092-8674(00)81814-0. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed